Equities

Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.51
  • Today's Change-0.04 / -2.58%
  • Shares traded228.14k
  • 1 Year change-74.23%
  • Beta1.1137
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 16-Sep-24
Select bar for recommendation details.
Recommendations16-Sep-24
Buy2
Outperform5
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Marinus Pharmaceuticals Inc have a median target of 9.00, with a high estimate of 13.00 and a low estimate of 2.00. The median estimate represents a 496.03% increase from the last price of 1.51.
High760.9%13.00
Med496.0%9.00
Low32.5%2.00

Earnings history & estimates in USD

On Aug 13, 2024, Marinus Pharmaceuticals Inc reported 2nd quarter 2024 losses of -0.600 per share. This result was in line with the consensus of the 11 analysts following the company and exceeded last year's 2nd quarter results by 1.64%.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate-0.36%
Marinus Pharmaceuticals Inc reported annual 2023 losses of -2.63 per share on Mar 05, 2024.
Average growth rate-75.36%
More ▼

Revenue history & estimates in USD

Marinus Pharmaceuticals, Inc. had 2nd quarter 2024 revenues of 8.06m. This missed the 9.50m consensus estimate of the 11 analysts following the company. This was 22.39% below the prior year's 2nd quarter results.
Average growth rate+7.59%
Marinus Pharmaceuticals, Inc. had revenues for the full year 2023 of 30.99m. This was 21.63% above the prior year's results.
Average growth rate+293.62%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.